Goldman Sachs analyst Corinne Johnson started Structure Therapeutics (GPCR) with an Early-Stage Biotech rating.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics Holds 2025 Annual Shareholders Meeting
- Structure Therapeutics, Inc.: Catalyst-Rich Outlook and Strategic Preparations Support Buy Rating
- Structure Therapeutics price target raised to $80 from $75 at H.C. Wainwright
- Structure Therapeutics, Inc.: Promising Pipeline and Strong Financial Position Drive Buy Rating